DOI QR코드

DOI QR Code

Estimating survival distributions for two-stage adaptive treatment strategies: A simulation study

  • Received : 2020.10.10
  • Accepted : 2021.07.15
  • Published : 2021.09.30

Abstract

Inference following two-stage adaptive designs (also known as two-stage randomization designs) with survival endpoints usually focuses on estimating and comparing survival distributions for the different treatment strategies. The aim is to identify the treatment strategy(ies) that leads to better survival of the patients. The objectives of this study were to assess the performance three commonly cited methods for estimating survival distributions in two-stage randomization designs. We review three non-parametric methods for estimating survival distributions in two-stage adaptive designs and compare their performance using simulation studies. The simulation studies show that the method based on the marginal mean model is badly affected by high censoring rates and response rate. The other two methods which are natural extensions of the Nelson-Aalen estimator and the Kaplan-Meier estimator have similar performance. These two methods yield survival estimates which have less bias and more precise than the marginal mean model even in cases of small sample sizes. The weighted versions of the Nelson-Aalen and the Kaplan-Meier estimators are less affected by high censoring rates and low response rates. The bias of the method based on the marginal mean model increases rapidly with increase in censoring rate compared to the other two methods. We apply the three methods to a leukemia clinical trial dataset and also compare the results.

Keywords

References

  1. Guo X and Tsiatis A (2005). A weighted risk set estimator for survival distributions in two-stage randomization designs with censored survival data, Int J Biostat, 1, 1-15.
  2. Johnson RW (2001). An introduction to the bootstrap, Teaching Statistics, 23, 49-54. https://doi.org/10.1111/1467-9639.00050
  3. Kidwell KM and Hyde LW (2016). Adaptive interventions and SMART designs: Application to child behavior research in a community setting, American Journal of Evaluation, 37, 344-363. https://doi.org/10.1177/1098214015617013
  4. Kidwell KM and Wahed AS (2013). Weighted log-rank statistic to compare shared-path adaptive treatment strategies, Biostatistics, 1-14.
  5. Kolitz JE et al. (2010). P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808, Blood, 116, 1413-1421. https://doi.org/10.1182/blood-2009-07-229492
  6. Kolitz JE et al. (2014). Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from CALG 19808, Cancer, 120, 1010-1017. https://doi.org/10.1002/cncr.28516
  7. Lunceford JK, Davidian M, and Tsiatis AA (2002). Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials, Biometrics, 48-57.
  8. Miyahara S and Wahed AS (2010). Weighted Kaplan-Meier estimators for two-stage treatment regimes, Statistics in medicine, 29, 2581-2591. https://doi.org/10.1002/sim.4020
  9. Nahum-Shani I et al. (2012). Experimental design and primary data analysis methods for comparing adaptive interventions, Psychological methods, 17, 457. https://doi.org/10.1037/a0029372
  10. Robins J, Rotnitzky A, and Zhao L (1994). Estimation of regression coefficients when some regressors are not always observed, Journal of the American Statistical Association, 89, 846-866. https://doi.org/10.1080/01621459.1994.10476818
  11. Rubin DB (1974). Estimating causal effects of treatments in randomized and nonrandomized studies, Journal of educational Psychology, 66, 688. https://doi.org/10.1037/h0037350
  12. Tang X and Melguizo M (2015). DTR: An R package for estimation and comparison of survival outcomes of dynamic treatment regimes, Journal of Statistical Software, 65, 1-28.
  13. Wahed AS and Tsiatis AA (2004). Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials, Biometrics, 60, 124-133. https://doi.org/10.1111/j.0006-341X.2004.00160.x